Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes

Laboratory Investigation

Volumn 86, Issue 3, 2006, Pages 262-274

  Gross, Marie Luise P ^a   Koch, Andreas ^a   Mühlbauer, Bernd ^b   Adamczak, Marcin ^a   Ziebart, Heike ^a   Drescher, Karla ^c   Gross, Gerhard ^c   Berger, Irina ^a   Amann, Kerstin U ^d   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c ABBOTT GMBH AND CO KG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Capillarization; Dopamine D3 receptor; Dopamine receptor antagonist; Glomerular cells; Progression; Type II diabetes

Indexed keywords

A 437203; ALBUMIN; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; PLACEBO; TRANDOLAPRIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BLOOD VESSEL INJURY; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HISTOLOGY; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; LEAN BODY WEIGHT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERFUSION; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SCORING SYSTEM; URINALYSIS; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; GENE EXPRESSION; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MALE; RATS; RATS, INBRED SHR; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 33244487764     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700383     Document Type: Article

References (47)

1. Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003;83:1267-1277.
2. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003;114:588-598.
3. Yamaguchi I, Yao L, Sanada H, et al. Dopamine D1A receptors and renin release in rat juxtaglomerular cells. Hypertension 1997;29:962-968.
4. Sanada H, Yao L, Jose PA, et al. Dopamine D3 receptors in rat juxtaglomerular cells. Clin Exp Hypertens 11997;9:93-105.
5. Ferguson M, Bell C. Two patterns of dopa decarboxylase immunoreactivity in sympathetic axons supplying rat renal cortex. Ren Physiol Biochem 1991;14:55-62.
6. Luippold G, Muhlbauer B. Dopamine D2 receptors mediate glomerular hyperfiltration due to amino acids. J Pharmacol Exp Ther 1998;286:1248-1252.
7. Luippold G, Schneider S, Stefanescu A, et al. Dopamine D2-like receptors and amino acid-induced glomerular hyperfiltration in humans. Br J Clin Pharmacol 2001;51:415-421.
8. Luippold G, Beilharz M, Muhlbauer B. Reduction of glomerular hyperfiltration by dopamine D(2)-like receptor blockade in experimental diabetes mellitus. Nephrol Dial Transplant 2001;16:1350-1356.
9. Luippold G, Schneider S, Vallon V, et al. Postglomerular vasoconstriction induced by dopamine D(3) receptor activation in anesthetized rats. Am J Physiol Renal Physiol 2000;278:F570-F575.
10. Tulp OL, Weng M. Effect of genetic dilution on development of diabetes, impaired glucose tolerance and in vitro glucose oxidation in LA/N-cp x SHR/N-cp F1 hybrid rats. Comp Biochem Physiol Comp Physiol 1992;101:403-408.
11. Marette A, Tulp OL, Bukowiecki LJ. Mechanism linking insulin resistance to defective thermogenesis in brown adipose tissue of obese diabetic SHR/N-cp rats. Int J Obes Relat Metab Disord 1991;15:823-831.
12. Marette A, Deshaies Y, Collet AJ, et al. Major thermogenic defect associated with insulin resistance in brown adipose tissue of obese diabetic SHR/N-cp rats. Am J Physiol 1991;261:E204-E213.
13. Schwarz U, Amann K, Orth SR, et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696-1705.
14. el Nahas AM, Bassett AH, Cope GH, et al. Role of growth hormone in the development of experimental renal scarring. Kidney Int 1991;40:29-34.
15. Gandhi M, Olson JL, Meyer TW. Contribution of tubular injury to loss of remnant kidney function. Kidney Int 1998;54:1157-1165.
16. Veniant M, Heudes D, Clozel JP, et al. Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 1994;46:421-429.
17. Weibel ER. Measuring through the microscope: development and evolution of stereological methods. J Microsc 1989;155(Part 3):393-403.
18. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001;60:1309-1323.
19. Amann K, Nichols C, Tornig J, et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-1011.
20. Gross ML, El-Shakmak A, Szabo A, et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-868.
21. Wolf G, Wenzel U, Ziyadeh FN, et al. Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats. Diabetologia 1999;42:1425-1432.
22. Canaan-Kuhl S, Ostendorf T, Zander K, et al. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int 1998;53:1143-1151.
23. Asico LD, Ladines C, Fuchs S, et al. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 1998;102:493-498.
24. Williams BC, Eglen A, Duncan FM, et al. The effect of sodium intake on the renin response to dopamine in superfused rat renal cortical cells. J Hypertens 1985;(Suppl 3):S267-S268.
25. DeFeo ML, Jadhav AL, Lokhandwala MF. Dietary sodium intake and urinary dopamine and sodium excretion during the course of blood pressure development in Dahl salt-sensitive and salt-resistant rats. Clin Exp Hypertens 1987;A9:2049-2060.
26. Racz K, Kuchel O, Buu NT. Abnormal adrenal catecholamine synthesis in salt-sensitive Dahl rats. Hypertension 1987;9:76-80.
27. Sakamoto T, Chen C, Lokhandwala MF. Lack of renal dopamine production during acute volume expansion in Dahl salt-sensitive rats. Clin Exp Hypertens 1994;16:197-206.
28. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000;75:S22-S26.
29. Hansen JM, Kanstrup IL, Richalet JP, et al. High altitude-induced albuminuria in normal man is enhanced by infusion of low-dose dopamine. Scand J Clin Lab Invest 1996;56:367-372.
30. Norman JT, Orphanides C, Garcia P, et al. Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 1999;7:463-469.
31. Stenvinkel P, Saggar-Malik AK, Wahrenberg H, et al. Impaired intrarenal dopamine production following intravenous sodium chloride infusion in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991;34:114-118.
32. Rudberg S, Lemne C, Persson B, et al. The dopaminuric response to high salt diet in insulin-dependent diabetes mellitus and in family history of hypertension. Pediatr Nephrol 1997;11:169-173.
33. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
34. Muhlbauer B, Kuster E, Luippold G. Dopamine D(3) receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiol Scand 2000;168:219-223.
35. Luippold G, Beilharz M, Wehrmann M, et al. Effect of dopamine D(3) receptor blockade on renal function and glomerular size in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 2005;371:420-427.
36. O'Connell DP, Vaughan CJ, Aherne AM, et al. Expression of the dopamine D3 receptor protein in the rat kidney. Hypertension 1998;32:886-895.
37. Barili P, Ricci A, Baldoni E, et al. Pharmacological characterisation and autoradiographic localisation of a putative dopamine D3 receptor in the rat kidney. Eur J Pharmacol 1997;338:89-95.
38. Barnett R, Singhal PC, Scharschmidt LA, et al. Dopamine attenuates the contractile response to angiotensin II in isolated rat glomeruli and cultured mesangial cells. Circ Res 1986;59:529-533.
39. Phillips AO, Baboolal K, Riley S, et al. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis 2001;37:400-410.
40. Endlich N, Endlich K. cAMP pathway in podocytes. Microsc Res Technol 2002;57:228-231.
41. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-877.
42. Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis 2003;41:S3-S7.
43. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001;37:720-727.
44. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-1509.
45. Wolf G, Chen S, Han DC, et al. Leptin and renal disease. Am J Kidney Dis 2002;39:1-11.
46. Han DC, Isono M, Chen S, et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001;59:1315-1323.
47. Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor beta in increasing type I collagen formation. Biochem Biophys Res Commun 2002;297:906-911.